
Immunotherapy in stage III non-small cell lung cancer
Cost-effectiveness of durvalumab consolidation therapy
3 COMENTÁRIOSCost-effectiveness of durvalumab consolidation therapy
3 COMENTÁRIOSToday and beyond
8 COMENTÁRIOSA historic dispute over the cause of cancer
4 COMENTÁRIOS